Phase 1 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced colorectal cancer, confirmed by a lab test on tissue or cell samples, and who are no longer able to receive standard treatments.
• People who are willing to have surgery or a biopsy to collect tumor tissue, which will be used to prepare the treatment used in this trial.
• People aged 18 to 70 years old.
• People who have at least one tumor that can be measured using standard imaging guidelines (called RECIST 1.1).
• People who are generally well enough to carry out light activity or desk work — rated 0 or 1 on a standard health performance scale (ECOG).
• People whose bone marrow, liver, kidneys, and other organs are working well enough to meet the trial's health requirements.
• People whose doctors estimate they are likely to live for at least 6 more months.

Who may not be able to join:

• People who received chemotherapy, radiation, biological therapy, hormone therapy, immunotherapy, or certain traditional Chinese medicine anti-cancer treatments within 2 weeks before the tissue sample is collected (with some specific exceptions — confirm with trial site).
• People who took part in another trial using an unapproved or experimental treatment within 4 weeks before the tissue sample is collected.
• People who had major surgery (not counting needle biopsies) within 4 weeks before the tissue sample is collected, had a serious injury, or who need planned surgery during the trial period.
• People who have taken high-dose steroid medications by mouth or injection (such as prednisone above a certain dose) within 14 days before the tissue sample is collected, to suppress the immune system (some forms of steroids used locally, such as eye drops, joint injections, or inhalers, may be exceptions — confirm with trial site).
• People who used certain immune-boosting medicines, such as thymosin, interleukin-2, or interferon, within 14 days before the tissue sample is collected.
• People who received a live vaccine within 4 weeks before the tissue sample is collected.
• People who still have side effects from previous cancer treatments that have not improved to a mild level (with some exceptions, such as hair loss — confirm with trial site).
• People who have cancer that has spread to the brain or the lining around the brain, and where those symptoms are active or not well controlled.
• People who have an active infection requiring ongoing antibiotic or antiviral treatment within 1 week before the tissue sample is collected.
• People who have a history of immune system deficiency, or who test positive for HIV.
• People who test positive for Hepatitis B, Hepatitis C, or syphilis.
• People who currently have a lung condition called interstitial lung disease.
• People with a serious history of heart or blood vessel disease, including certain irregular heart rhythms, recent heart attack, heart failure, stroke, aortic dissection, or other serious cardiac events within the past 6 months; uncontrolled high blood pressure; or significant structural heart problems (confirm details with trial site).
• People with active or past autoimmune diseases (such as lupus, rheumatoid arthritis, or vasculitis), with some possible exceptions for people with stable thyroid autoimmune conditions or well-managed type 1 diabetes (confirm with trial site).
• People who previously had a serious immune-related side effect (grade 3 or higher) from immunotherapy.
• People who have uncontrolled fluid build-up in body cavities (such as around the lungs or abdomen), which the trial doctor judges to be a safety concern.
• People with a known dependence on alcohol or drugs.
• People with mental health conditions or who are unlikely to be able to follow the trial requirements.
• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.